News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Subscribe To Our Newsletter & Stay Updated
